AstraZeneca PLC is a global biopharmaceutical giant operating within the Healthcare sector. With a substantial market capitalization of 177.73 Billion, it stands as a leading player in the general drug manufacturing industry, focusing on the discovery, development, and commercialization of prescription medicines.

Based on our technical scoring system, AstraZeneca PLC currently registers a Strong Sell rating with a total score of -5. This negative outlook is driven by several key indicators. The primary signal is the Trend Score (-2), as the current price of GBp11,460.00 is significantly below its 200-day moving average (GBp13,778.20), indicating a powerful long-term downtrend. This is further confirmed by the Trend Strength Score (-1), with a high ADX of 55.83 signaling a very strong trend, which is clearly bearish as the DMI- line is dominant. Additionally, the MACD Score (-1) shows a negative histogram, confirming bearish momentum. The Volume Score (-1) also points to distribution, as the OBV is below its moving average, suggesting selling pressure is outpacing buying. The RSI, at 32.89, is neutral and does not contribute to the score, but it is approaching oversold levels.

In conclusion, the technical indicators present a compellingly bearish case for AstraZeneca. While the company's fundamentals show a reasonable P/E ratio of 23.15, the technical weakness is overwhelming. The provided dividend yield appears unusually high and may warrant further investigation. The absence of recent reported EPS data and a very distant next earnings date of 30/10/2026 limits our ability to gauge current performance against market expectations. Therefore, the strong negative technical signals are the dominant factor, justifying the Strong Sell rating at this time.